Pathology & Oncology Research

, Volume 19, Issue 3, pp 529–537

MicroRNA-335 Acts as a Candidate Tumor Suppressor in Prostate Cancer

  • Si-wei Xiong
  • Tian-xin Lin
  • Ke-wei Xu
  • Wen Dong
  • Xiao-hui Ling
  • Fu-neng Jiang
  • Guo Chen
  • Wei-de Zhong
  • Jian Huang
Research

DOI: 10.1007/s12253-013-9613-5

Cite this article as:
Xiong, S., Lin, T., Xu, K. et al. Pathol. Oncol. Res. (2013) 19: 529. doi:10.1007/s12253-013-9613-5

Abstract

MicroRNA-335 (miR-335) acts as a tumor suppressor or a tumor promoter in different human malignancies. However, the involvement of miR-335 in prostate cancer (PCa) is still unclear. The purpose of this study was to investigate the functional and clinical significance of miR-335 in PCa. miR-335 expression in 3 PCa cell lines (LNCaP/DU145/PC3) and in 20 clinical PCa tissues were detected by real-time quantitative reverse transcriptase-PCR compared with corresponding controls. The function of miR-335 was investigated for cell proliferation, invasion and migration in PCa cells transfected with agents containing EGFP-miR-335 expression vector. Additionally, miR-335 expression in 104 clinical PCa tissues was detected by in situ hybridization. Its assocaitions with clinicopathological features and prognosis in patients with PCa were also determined. miR-335 was significantly down-regulated in PCa cell lines than in the normal prostate cell line (P < 0.01). With the similar results in vitro, the reduced expression of miR-335 was also found in human PCa tissues comparing with paired adjacent benign prostate tissues (P < 0.05). Moreover, the increased expression of miR-335 suppressed cell proliferation, invasion and migration of PCa cell lines in vitro. Turning to its clinical significance, the low expression of miR-335 was significantly associated with high Gleason Score (P = 0.04), advanced clinical stage (P = 0.04), and positive metastasis (P = 0.02), but not with prognosis in PCa patients. Our data demonstrated for the first time the inhibitory effect of miR-335 on cell proliferation and invasion for PCa cells. The loss of this microRNA might be associated with clinical progression of PCa patients.

Keywords

Prostate cancer microRNA-335 Tumor suppressor Clinicopathological feature Prognosis 

Copyright information

© Arányi Lajos Foundation 2013

Authors and Affiliations

  • Si-wei Xiong
    • 1
    • 2
  • Tian-xin Lin
    • 1
  • Ke-wei Xu
    • 1
  • Wen Dong
    • 1
  • Xiao-hui Ling
    • 2
  • Fu-neng Jiang
    • 2
  • Guo Chen
    • 2
  • Wei-de Zhong
    • 2
    • 3
    • 4
  • Jian Huang
    • 1
  1. 1.Department of UrologySun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhouChina
  2. 2.Department of UrologyGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, Guangzhou Medical UniversityGuangzhouChina
  3. 3.Guangdong Provincial Institute of NephrologySouthern Medical UniversityGuangzhouChina
  4. 4.Urology Key Laboratory of Guangdong ProvinceGuangzhou Medical CollegeGuangzhouChina

Personalised recommendations